CRISPR Therapeutics vs Option Care Health

CRISPR Therapeutics (CRSP), health care, and Option Care Health (OPCH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Option Care Health is worth $4.7B on the stock market and CRISPR Therapeutics $3.9B: Option Care Health is valued at 22% more. CRISPR Therapeutics's operating margin in its latest fiscal year was -18934% and Option Care Health's 5.98%. Over the past year CRISPR Therapeutics's share price has moved -24.5% and Option Care Health's +12.1%.

Key facts

CRISPR Therapeutics market value
$3.9B
Option Care Health market value
$4.7B
Option Care Health P/E
22.9
CRISPR Therapeutics revenue
$3.5MFY to 2025-12-31
Option Care Health revenue
$5.6BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

CRISPR Therapeutics vs Option Care Health: every measure side by side
Measure CRISPR Therapeutics Option Care Health
SectorHealth CareHealth Care
Country Switzerland United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$3.9Blower$4.7Bhigher
Revenue$3.5Mlower$5.6Bhigher
Earnings-$581.6Mlower$207.6Mhigher
Employees—6,528
Total assets$2.3Blower$3.5Bhigher
Valuation
P/E—22.9
P/S1110higher0.8lower
P/B—3.6
Dividend yield—0.00%
Profitability
Operating margin-18934%lower5.98%higher
Balance sheet
Net assets$1.9Bhigher$1.3Blower
Total liabilities$343.4Mlower$2.1Bhigher
Total debt—$1.2B
Cash on hand$347.6Mhigher$232.6Mlower
Price change
Today-0.54%lower-0.25%higher
1 year-24.5%lower+12.1%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

CRISPR Therapeutics only (1)

Option Care Health only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns CRSP · Who owns OPCH

Further comparisons

Learn

Questions and answers

Which is bigger, CRISPR Therapeutics or Option Care Health?

By market value, Option Care Health is the larger: $4.7B against $3.9B for CRISPR Therapeutics. By revenue in its latest fiscal year, Option Care Health is the larger: $5.6B against $3.5M for CRISPR Therapeutics.

Which has the higher operating margin?

Option Care Health: 5.98%, against -18934% for CRISPR Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both CRISPR Therapeutics and Option Care Health?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds CRISPR Therapeutics and 1 holds Option Care Health.

Cite this page

Funkfolio, “CRISPR Therapeutics vs Option Care Health”, data as of 18 November 2026. https://funkfolio.com/compare/crsp-vs-opch

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.